11. SEGMENT INFORMATION (Details) - USD ($) |
3 Months Ended | 12 Months Ended | |
|---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2016 |
Dec. 31, 2016 |
|
| Product sales, net | $ 3,764,191 | $ 2,422,678 | |
| Gross profit | 2,433,003 | 1,625,635 | |
| Gain on change in derivative liability | 210,600 | 0 | $ 0 |
| Royalty buy-out | (2,432,000) | 0 | |
| Selling, general and administrative | (3,676,710) | ||
| Research and development | (188,716) | (141,813) | |
| Operating (loss) income | (3,653,823) | (1,205,423) | |
| Consumer Products [Member] | |||
| Product sales, net | 3,764,191 | ||
| Gross profit | 2,433,003 | ||
| Gain on change in derivative liability | 210,600 | ||
| Royalty buy-out | 0 | ||
| Selling, general and administrative | (3,605,177) | ||
| Research and development | (49,033) | (141,813) | |
| Operating (loss) income | (1,010,607) | ||
| Specialty Pharmaceuticals [Member] | |||
| Product sales, net | 0 | ||
| Gross profit | 0 | ||
| Gain on change in derivative liability | 0 | ||
| Royalty buy-out | (2,432,000) | ||
| Selling, general and administrative | (71,533) | ||
| Research and development | (139,683) | $ 0 | |
| Operating (loss) income | $ (2,643,216) | ||
| X | ||||||||||
- Definition Amount of increase (decrease) in the fair value of derivatives recognized in the income statement. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Definition The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|